Table 2

Association between the IC biomarkers and the risk of any CVD in unadjusted, minimally adjusted, and final adjusted Cox models

UnadjustedAdjusted for age and HbA1cFinal models*
HR (95% CI)**P valueHR (95% CI)**P valueHR (95% CI)**P value
DCCT baseline (100 events, n = 518)
 AGE-LDL-IC (mg/L)1.31 (1.06, 1.60)0.0111.28 (1.04, 1.57)0.0191.21 (0.98, 1.50)0.083
 MDA-LDL-IC (mg/L)1.28 (1.05, 1.56)0.0151.29 (1.06, 1.58)0.0121.24 (1.01, 1.52)0.045
 oxLDL-IC (mg/L)1.46 (1.14, 1.87)0.0031.45 (1.14, 1.84)0.0021.33 (1.04, 1.72)0.025
DCCT closeout (93 events, n = 500)
 AGE-LDL-IC (mg/L)1.28 (1.05, 1.57)0.0161.22 (1.01, 1.49)0.0451.02 (0.81, 1.28)0.901
 MDA-LDL-IC (mg/L)1.32 (1.07, 1.63)0.0101.31 (1.06, 1.63)0.0121.16 (0.93, 1.44)0.191
 oxLDL-IC (mg/L)1.58 (1.24, 2.01)<0.0011.49 (1.17, 1.88)0.0011.21 (0.93, 1.58)0.150
All measurements (100 events, n = 518)
 AGE-LDL-IC (mg/L)1.37 (1.14, 1.65)0.0011.31 (1.08, 1.58)0.0071.17 (0.96, 1.44)0.120
 MDA-LDL-IC (mg/L)1.33 (1.09, 1.62)0.0051.32 (1.07, 1.63)0.0111.20 (0.97, 1.48)0.093
 oxLDL-IC (mg/L)1.56 (1.26, 1.93)<0.0011.47 (1.18, 1.81)<0.0011.27 (1.03, 1.57)0.028
  • P values <0.05 are presented in boldface type.

  • *Adjusted for age, mean HbA1c, cohort, sex, mean SBP, pulse, (log) triglycerides, mean LDL, (log) AER, and duration of T1D.

  • **Per 1 unit increase in the log-transformed biomarker value. The HR per (for example) a 25% increase in the biomarker (or equivalently, a 1.25-fold change) is given by HR^log(1.25), where “^” denotes “to the power of.” Biomarkers are amount per milligram of apoB contained in the IC, using serum total apoB/L.